WEDNESDAY 16th OCTOBER 2013 COMMENCING 09.30 AM
(UNTIL 4.00 PM APPROX)
AT THE ANGEL HOTEL, ABERGAVENNY, NP7 5EN

AGENDA

1. Welcome and introduction
2. Apologies
3. Declarations of interest
4. Minutes of previous meeting

Enclosure

To protect commercial confidentiality, the first appraisal will be conducted in private. The final appraisal recommendation will be announced in public

5. Appraisal 1 – Full submission (WPAS)
Elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate (Stribild®) for the treatment of human immunodeficiency virus-1 (HIV-1) infection in adults aged 18 years and over who are antiretroviral-treatment-naive or are infected with HIV-1 without known mutations associated with resistance to any of the three antiretroviral agents in Stribild

Appendices

6. Chairman’s report (verbal update)

7. Appraisal 2 – Full submission (reappraisal)
Pegvisomant (Somavert®) is indicated for the treatment of patients with acromegaly who have had an inadequate response to surgery and/or radiation therapy and in whom an appropriate medical treatment with somatostatin analogues did not normalise IGF-I concentrations or was not tolerated

Appendices

8. Appraisal 3 – Full submission
Tegafur/gimeracil/oteracil (Teysuno®) for the treatment of advanced gastric cancer in adults when given in combination with cisplatin

Appendices
9. **Appraisal 4 – Full submission**
5-aminolaevulinic acid (Ameluz®) for the treatment of actinic keratosis of mild to moderate intensity on the face and scalp (Olsen grade 1 to 2)

10. **Appraisal 5 – Full submission**
Lisdexamfetamine dimesylate (Elvanse®) as part of a comprehensive treatment programme for attention deficit/hyperactivity disorder (ADHD) in children aged 6 years of age and over when response to previous methylphenidate treatment is considered clinically inadequate. Treatment must be under the supervision of a specialist in childhood and/or adolescent behavioural disorders

11. **Appraisal 6 – Limited submission**
Raltegravir (Isentress®) is indicated in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus (HIV-1) infection in adolescents and children from the age of 2 years

12. **Reappraisal following Independent Review**
Pazopanib (Votrient®) for the treatment of adult patients with selective subtypes of advanced soft tissue sarcoma who have received prior chemotherapy for metastatic disease or who have progressed within 12 months after (neo)adjuvant therapy

13. **AWPAG update (draft minutes of September 2013 meeting)**

14. **Primary Care Prescribing Analysis – Gluten Free**

15. **Tramadol and Morphine National Prescribing Indicator (NPI) report**

16. **NPI Quarterly Report**

17. **Prescribing of Denosumab (Prolia®) in Wales (Review)**

18. **All Wales Risk/Benefit Assessment Tool for Oral Anticoagulant Treatment in People with Atrial Fibrillation**

19. **Supply and administration of intranasal fentanyl spray in non-specialist palliative inpatient settings**

20. **Date of next meeting:**
Wednesday 20th November in Cardiff